Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dyne Therapeutics, Inc.

9.91
+0.58006.22%
Post-market: 9.910.00000.00%16:32 EDT
Volume:3.26M
Turnover:32.43M
Market Cap:1.12B
PE:-2.94
High:10.11
Open:9.48
Low:9.30
Close:9.33
Loading ...

Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now

Insider Monkey
·
06 Feb

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

Zacks
·
03 Feb

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Zacks
·
31 Jan

Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround

Zacks
·
28 Jan

Dyne Therapeutics Gains ‘Buy’ Rating Following FDA Fast Track Designation and Promising Trial Results

TIPRANKS
·
22 Jan

Dyne Therapeutics Says US FDA Grants Fast Track tag to Neuromuscular Disease Therapy

MT Newswires Live
·
21 Jan

Dyne Gets FDA Fast-Track Status for Neuromuscular Product Candidate

Dow Jones
·
21 Jan

BRIEF-Dyne Therapeutics Receives FDA Fast Track Designation For Dyne-101

Reuters
·
21 Jan

Dyne Therapeutics receives FDA Fast Track designation for DYNE-101

TIPRANKS
·
21 Jan

Dyne Therapeutics Inc - to Submit for U.S. Accelerated Approval in H1 2026

THOMSON REUTERS
·
21 Jan

Dyne Therapeutics Receives FDA Fast Track Designation for Dyne-101 for the Treatment of Myotonic Dystrophy Type 1

THOMSON REUTERS
·
21 Jan

Dyne Therapeutics Price Target Maintained With a $45.00/Share by RBC Capital

Dow Jones
·
15 Jan

Positive Outlook for Dyne Therapeutics as DYN-101 Shows Promising Clinical Results and Strategic Regulatory Advancements

TIPRANKS
·
11 Jan

Dyne Therapeutics: Positive Phase 1/2 Trial Results for DYNE-101 Lead to Buy Rating and Overweight Stock Recommendation

TIPRANKS
·
11 Jan

Small U.S. Stocks Close Lower; Dyne Therapeutics Posts Biggest Loss

Dow Jones
·
11 Jan

Dyne Therapeutics’ Promising Data and Strategic Moves Drive Buy Rating by Andrew Fein

TIPRANKS
·
11 Jan

H.C. Wainwright keeps Buy on Dyne Therapeutics after data

TIPRANKS
·
11 Jan

RBC remain buyers of Dyne Therapeutics after DM1 and DMD data

TIPRANKS
·
11 Jan

Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall

MT Newswires Live
·
10 Jan

Dyne Therapeutics Inc - Plans U.S. Accelerated Approval Submission for Dyne-101 in H1 2026

THOMSON REUTERS
·
10 Jan